E. R. Squibb & Sons, L.L.C.;Oxford BioTherapeutics Ltd
发明人:
申请号：
EP10708470.9
公开号：
EP2403878B1
申请日:
2010.03.05
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.
